Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).

At the 6-week mark, higher NLR was associated with worse objective response rates (ORR) as well as shorter progression-free survival (PFS), and overall survival (OS) compared with those with lower NLR, according to Lalani.

Patients who had a decrease in NLR by 25% or more from baseline to 6 weeks had more favorable outcomes in terms of PFS and OS compared with patients who had an increase of 25% or more, states Lalani.

Videos

Dr. Lalani on a Study of Neutrophil-Lymphocyte Ratio in RCC

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses neutrophil-lymphocyte ratio in renal cell carcinoma (RCC).

The ratio of neutrophil to lymphocytes was compared in a study of patients with RCC treated with immunotherapy.

Neutrophils reflect the inflammatory cascade in patients with cancer, says Lalani, and lymphocytes are an important antitumor agent.

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses neutrophil-lymphocyte ratio in renal cell carcinoma.

Aly-Khan Lalani, MD

Articles

Dr. Lalani on a Study of Neutrophil-Lymphocyte Ratio in RCC

Dr. Lalani on Neutrophil-Lymphocyte Ratio in RCC